|
Oral, Non-Steroidal Anti-Inflammatory Drug (NSAID) with low gastro-intestinal toxicity and rapid excretion.
Composition
CU-ALGESIC is a patented chelate formulation of Copper Indomethacin, available as:
CU-ALGESIC EQUINE ORAL PASTE ANTI-INFLAMMATORY FOR HORSES:
Active constituent: Copper indomethacin 40 mg/g
CU-ALGESIC GRANULES:
Active constituent: Copper indomethacin 10 mg/g
Features and Benefits
CU-ALGESIC is a potent non-steroidal anti-inflammatory and analgesic for the treatment of acute and sub-acute musculo-skeletal / locomotor inflammatory conditions in horses.
CU-ALGESIC provides excellent analgesia, as well as potent anti-inflammatory activity, with very low gastro-intestinal toxicity, unlike most other NSAIDs. CU-ALGESIC is the only NSAID known to be a free radical scavenger.
CU-ALGESIC has a once daily dosage regime, plus predictable short excretion rates, even with repeated dosing.
Indications
CU-ALGESIC is indicated for conditions requiring a potent anti-inflammatory action with excellent analgesia, with reduction of side effects usually associated with long term use of other NSAIDs. These conditions include acute and sub-acute musculoskeletal / locomotor inflammatory conditions such as osteitis (shin soreness), pedal osteitis, navicular disease, sesamoiditis, synovial arthritis, osteoarthritis, bursitis, tenosynovitis, spondylitis, tendonitis and ligament inflammation, and ocular conditions such as uveitis.
Actions:
Copper chelation of the parent NSAID (Indomethacin) produces a unique pharmacological substance with significantly increased anti-inflammatory potency, broader inhibition of inflammatory reactions, and virtual elimination of adverse side effects, especially gastro-intestinal ulceration.
Copper indomethacin is a prostaglandin cyclo-oxygenase 1 & 2 (Cox 1 & 2) inhibitor. Additionally, the lipoxygenase pathway is inhibited. It also inhibits kallikreins, and thereby bradykinin formation, which, with histamine and prostaglandins, produce the pain of inflammation.
Copper chelates are free radical scavengers by Superoxide Dismutase mimetic activity. Superoxide free radicals are involved in degradation of hyaluronic acid in inflamed joints and in perpetuation of the inflammatory cycle. Copper indomethacin is therefore ideal for use in joint disease, and is indicated for prevention of reperfusion injury. The broad combination of modes of action helps to reduce gastro-intestinal and renal toxicity.
CU-ALGESIC is rapidly absorbed from the gastro-intestinal tract. Peak plasma levels are achieved within 3 - 4 hours of administration. Plasma half-life of CU-ALGESIC in the horse is approximately 24 hours. CU-ALGESIC is rapidly and predictably excreted, provided hepatic and renal function are normal.
Copper indomethacin may be used with caution as subsequent oral NSAID therapy following parenteral treatment with other NSAIDs (e.g. phenylbutazone or salicylates). There is no evidence of either synergy or antagonism between copper indomethacin and other NSAIDs. Use of two NSAIDs together generally summate therapeutic and toxic effects, and extends clearance times. Renal or hepatic conditions may alter the pharmacokinetics.
Safety in young foals or during pregnancy has not been conclusively demonstrated, and veterinarians should exercise normal caution in prescribing anti-inflammatories during these times.
Dosage and Administration
CU-ALGESIC GRANULES: 1 level scoop equals 20 g
Give 40 g/450 kg bodyweight on food initially, then 20 - 40 g once daily thereafter.
CU-ALGESIC EQUINE PASTE: Plunger is marked in 5 g increments
Give 10 g / 500 kg bodyweight by direct oral dosing initially, then 5 g / 500 kg once daily thereafter (i.e. 1 g per 100 kg bodyweight once daily)
Presentation
Granules: 10 mg/g, 200 g tub (10 day course)
Storage
Store below 25o C (air conditioning). Protect from moisture.
Poisons Schedule
S4 (Veterinary Prescription Only)
APVMA Approval Number
Granules: 40301
Trainers Tips:
|
